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ABSTRACT 
Aggregation of α-synuclein (αSN) is implicated 
in neuronal degeneration in Parkinson’s disease 
and has prompted searches for natural 
compounds inhibiting αSN aggregation and 
reducing its tendency to form toxic oligomers. Oil 
from the olive tree (Olea europaea L.) represents 
the main source of fat in the Mediterranean diet 
and contains variable levels of phenolic 
compounds, many structurally related to the 
compound oleuropein. Here, using αSN 
aggregation, fibrillation, size-exclusion 
chromatography–multi-angle light scattering 
(SEC-MALS)-based assays, and toxicity assays, 
we systematically screened the fruit extracts of 15 
different olive varieties to identify compounds 
that can inhibit αSN aggregation and oligomer 
toxicity and also have antioxidant activity. 
Polyphenol composition differed markedly 
among varieties. The variety with the most 
effective antioxidant and -aggregation activities, 
Koroneiki, combined strong inhibition of αSN 
fibril nucleation and elongation with strong 
disaggregation activity on preformed fibrils and 
prevented the formation of toxic αSN oligomers. 
Fractionation of the Koroneiki extract identified 
oleuropein aglycone, hydroxy oleuropein 
aglycone, and oleuropein as key compounds 
responsible for the differences in inhibition 
across the extracts. These phenolic compounds 
inhibited αSN amyloidogenesis by directing αSN 
monomers into small αSN oligomers with lower 
toxicity, thereby suppressing the subsequent fibril 
growth phase. Our results highlight the molecular 
consequences of differences in the level of 
effective phenolic compounds in different olive 
varieties, insights that have implications for long-
term human health.  
 
Parkinson’s Disease (PD), the second most 
common neurodegenerative disease, is 
characterized by the degeneration of 
dopaminergic neurons in the substantia nigra 
pars compacta due to deposition of intracellular 
inclusions known as Lewy Bodies (LBs). These 
deposits can spread from cell to cell in a prion-
 http://www.jbc.org/cgi/doi/10.1074/jbc.RA118.005723The latest version is at 
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like fashion (1–4), leading to rigid posture, 
uncertain pace, and resting tremor. The major 
component of LBs is the 140-residue protein α-
synuclein (αSN) which consists of three main 
regions: an amphiphilic N-terminal part, a non-
amyloid hydrophobic β-peptide component 
(NAC), and an acidic C-terminus. The NAC 
region makes up the fibril core of amyloid fibril 
(5). Although monomeric αSN is intrinsically 
disordered (5, 6), it readily aggregates to 
oligomers, protofilaments, and fibrils (7, 8). αSN 
aggregation is extremely complex and depends 
on many different pathways and factors (9). The 
most toxic species, oligomers accumulate in the 
early stages of the fibril formation process and are 
thought to cause membrane destabilization (10), 
cytoskeletal changes (11, 12), mitochondrial 
dysfunction (11, 13, 14), and enhanced oxidative 
stress (11, 12, 15). 
There has been an intense hunt for molecules 
which prevent αSN fibrillation and 
oligomerization and/ or reduce the toxicity of 
preformed aggregated species. Inhibiting the 
interaction of oligomers with membranes, 
decreasing the production of reactive oxygen 
species (ROS) (16) and / or curbing rising 
cytoplasmic Ca2+ levels are very challenging. 
The olive tree (Olea europaea) is major 
source of fat in the Mediterranean diet (MeDi) 
(17), characterized by high plant food content. 
The MeDi is rich in antioxidants found in olive or 
other plant foods which may help lower oxidative 
stress in brain aging by affecting the expression 
of genes related to oxidative stress and markers 
of lipid oxidation (18) as well as protecting cells 
against oxidative damage (19). Olive phenolic 
compounds protect against a number of chronic 
degenerative conditions and are also implicated 
in the antioxidant, analgesic, anti-inflammatory, 
antitumor, antiviral properties of the olive (20, 
21). They also inhibit self-assembly of Aβ42, tau 
and αSN (22–24) into amyloids and toxic 
aggregates, possibly by preventing π–π and /or 
hydrophobic interactions (25, 26) and by 
redirecting these proteins into alternative 
nontoxic aggregates. Palazzi et al showed that 
oleuropein aglycone keeps αSN unfolded, 
rescues cells from oligomer toxicity, probes 
disaggregation of αSN aggregation, and prevents 
αSN binding to membranes (27). It has also been 
shown that olive biophenols could reduce the 
enzyme-induced toxicity associated with the 
oxidative stress involved in the progression of 
Alzheimer’s disease (AD) (28). Among these 
compounds, some such as phenolic acids and 
flavonoids are found in many fruits. However, the 
secoiriods are present exclusively in plants 
belonging to the family of Olearaceae which 
includes Olea europaea L. (29). Secoiriods 
include oleuropein (responsible for the bitter taste 
of olive fruits ) and structurally related 
glucosides. The content of the polyphenols of 
olive fruit depends on the olive cultivar and the 
fruit ripening stage (30, 31). There are hundreds 
of olive varieties, classified based on their origin. 
Selection and promotion of beneficial 
polyphenol- rich olive varieties for long-term use 
may help combat PD at the population level. 
While we do not claim that overall effects of 
a Mediterranean diet can be reproduced in their 
entirety by one or a few specific compounds, it is 
of basic interest to compare different olive 
varieties and establish causal relationships 
explaining their different effects. Comparison of 
complex mixtures such as different olive varieties 
under the controlled conditions has the potential 
to provide simple and straightforward 
information about the most important 
contributors to anti-aggregative and thus 
potentially anti-PD effects. Accordingly, we 
systematically screened extracts from different 
olive varieties for their ability to inhibit αSN 
fibrillation and formation of toxic aggregates. 
The assays monitored (a) kinetics, extent and end 
products of αSN fibrillation; (b) formation of 
toxic oligomers, disaggregation of preformed 
fibrils, induced changes in αSN through 
interaction with anionic vesicles and vesicle 
permeabilization induced by oligomers in the 
presence and absence of the extracts, and (c) 
toxicity of both extracts and αSN aggregates 
formed in the presence of extracts. The assays 
identified the extract, that most efficiently 
inhibited αSN fibrillation. The best extract in 
inhibiting αSN fibrillation was fractionated and 
the compounds present in these fractions were 
identified by LC-MS analysis.  
 
Results 
Selection of Olive Fruits and Preparation of 
the Extracts  
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Methanolic extracts were obtained from 
fruits of different olive varieties (Table S1). Of 
these, the Mediterranean varieties Koroneiki, 
Arbequina, and Picual are the world’s most 
prestigious varieties for super high density 
cultivation systems with excellent oil quality 
characteristics. (32). Zard, Mari, and Rowghani 
are three prevailing varieties in Iran primarily 
used in olive oil production. The third group 
consisted of nine Iranian Tarom olive varieties 
(T10, T15, T16, T17, T18, T20, T22, T23 and 
T24).  
 
Screening against αSN Aggregation Based on 
ThT Screening Assays 
We first screened extracts for their ability to 
inhibit αSN aggregation using different ThT-
based plate reader assays. αSN aggregation in 
PBS buffer was accelerated by shaking in the 
presence of glass beads (31).  
In the fibrillation assay, all 15 extracts 
showed an aggregation-inhibitory effect at 0.025 
and 0.3 mg/mL by reducing the end-point ThT 
fluorescence level, though to different extents. At 
0.3 mg/mL, 7 of the 15 extracts (T10, T17, T20, 
T23, T24, Rowghani, and Koroneiki, in blue in 
Supplementary Fig. S1A and B) reduced end-
point ThT levels to 1-15 % of the control in the 
absence of extracts. The following experiments 
described in this paper focus only on these most 
effective 7 extracts. Dose-response curves were 
then recorded (Fig. 1A) and the normalized 
maximum ThT intensity (Fig. 1B) was used to 
obtain IC50 values (Eq.1) of the 7 top-ranked 
extracts (Fig. 1C). Here, the Koroneiki extract 
emerged as the best inhibitor. The Finke-Watzky 
model (Eq. 2) was fitted to the ThT kinetic data 
(kinetic data are summarized in Fig. 1D-F) to 
obtain two central parameters, namely t½ (the 
time required to produce half the total product) 
and ν (the rate of growth at t½), from which the 
lag or nucleation time tN could be calculated. The 
extracts reduced the level of fibrillation to 
different extents. All extracts except T24 
produced a concentration-dependent reduction of 
v and increase of t½ compared to control.  
Far-UV circular dichroism spectroscopy 
(CD), SDS-PAGE, and TEM images validated 
ThT data by providing independent 
measurements of the extent of fibrillation and the 
structure of the final aggregates. Remarkably, 
several of the extracts maintained αSN in a 
largely unfolded conformation (Fig. 2A-C), 
particularly at 0.3 mg/mL extract. The 
normalized β-sheet content (%) of αSN is shown 
in Fig. 2D. The Koroneiki extract was 
particularly effective at retaining the unfolded 
conformation of αSN, and its preeminence 
compared to the other extracts became more 
obvious as the extract concentration was reduced 
to 0.15 and 0.1 mg/mL. T17, T20, T23, and T24 
were least efficient in this regard, in good 
agreement with the ranking from the fibrillation 
assay.  
SDS-PAGE was used to analyze the amount 
of soluble αSN in the supernatant after 
centrifugation. The 7 extracts significantly 
increased the amount of monomer left in the 
solution after 24 h incubation (Fig. 2E and Fig. 
S2). Low, but detectable amounts of dimers and 
larger aggregates are also visible in the presence 
of some of the extracts. For additional 
confirmation, the supernatants of the incubated 
samples of αSN in the absence and presence of 
0.3 mg/ml of Koroneiki were run on a gel 
filteration column. As shown in Fig. 2F, 
Koroneiki significantly increased the amount of 
monomer left in the solution after 24 h 
incubation. Two populations of oligomers were 
also detectable after gel filteration of samples 
with Koroneiki. 
The effect of 0.3 mg/ml extract on the 
morphology of endpoint αSN aggregates was 
analyzed by TEM (Fig. 2G and associated table). 
While the limited quantitative output from these 
TEM analyses preclude detailed comparison with 
ThT parameters such as lag time and growth 
rates, there is good qualitative agreement: 
Koroneiki and Rowghani extract completely 
suppress fibril formation and only oligomers are 
detectable, just as they very efficiently suppress 
ThT signals. The other extracts reduce fibril 
formation to a somewhat smaller extent, but still 
lead to significant reductions compared to the 
control, consistent with their overall reduction of 
ThT signal. 
 
Olive  Fruit Extracts Induce Formation of 
Different Oligomers  
To study the effect of the extracts on the 
formation of soluble aggregates, we prepared 
oligomeric species of αSN in the presence and 
 by guest on January 20, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
4 
 
absence of 0.15 mg/ml extracts. While fibrillation 
of αSN is a slow process with lag times of 10-20 
h depending on protein concentration (33), 
oligomer formation occurs over a few (<5) hours. 
We have previously shown that during the 
oligomerization (900 rpm, 37 ºC), αSN forms two 
populations of oligomers, largely elongated 
oligomers and small spherical oligomers, which 
increase slowly over time (7, 34). The small 
oligomers, estimated to contain ∼ 30 monomers, 
form a compact prolate ellipsoid core with a 
number of flexible chains protruding from the 
surface into the solution, while the larger 
oligomers are concatemers of the smaller ones 
(34).  
We used SEC-MALS (Fig. 3A for Koroneiki 
and Fig. S3 for the others), a technique in which 
species are separated according to hydrodynamic 
radius on a SEC column, after which the 
concentration of the species are obtained from the 
peak area under the MALS peaks. We did not 
estimate oligomer concentration based on 
absorption at 280 or 215 nm since extract binding 
to the oligomers could affect absorption. Instead 
we used MALS data to allow more direct 
comparison of oligomer yields. This ranked the 
amount of large oligomers formed in the presence 
of the extracts in the following order: T23 > 
Rowghani > T10 ≈ T17 ≈ T24> Koroneiki> T20, 
which differed significantly from that of the small 
oligomers (Koroneiki> T10> T23 ≈ Rowghani ≈ 
T10 ≈ T17 ≈ T 24). In all cases, the level of 
monomers was relatively unchanged, indicating 
that most αSN remained unaggregated.  
 
Olive Fruit Extracts Disaggregate Preformed 
Fibrils  
We next used gel filtration to address 
whether overnight incubation with extracts could 
disaggregate existing αSN fibrils. We monitored 
this process by absorption at 215 nm, since we 
were mainly concerned with the appearance of 
soluble αSN. Addition of olive extracts led to an 
increase in the monomer peak, as well as the 
formation of soluble oligomers (eluting at 5-10 
ml), particularly in the presence of 0.15 mg/mL 
of Koroneiki extract (Fig. 3B). Additional peaks 
eluting after the αSN monomer peak are C-
terminal fragments of αSN formed by chemical 
cleavage after long-term incubation (C. Sahin et 
al., unpublished results). Thus existing fibrils 
could be disaggregated by Koroneiki extract at 
concentrations which also completely inhibited 
aggregation. The other extracts had less dramatic 
effects (Fig. S4), though T17 and T20 extracts in 
particular increased the monomer population to 
some extent.  
 
Olive Fruit Extracts Inhibit Fibril Elongation  
To determine whether or not the extracts 
could affect elongation of existing fibrils, short 
fibrillar seeds (5%) were added to monomeric 
αSN. This bypasses the nucleation step and 
allows us to study the elongation of existing 
fibrils. Koroneiki extract was the most effective 
inhibitor in both shaking and non-shaking assays, 
leading to a very extended lag phase of 
fibrillation (≈10 h) under shaking conditions and 
completely suppressing fibril growth over a 45 h 
observation period in the absence of shaking (Fig. 
3C and D). The other extracts reduced elongation 
rates to different extents. T23 extract performed 
most poorly in both assays, while T17, T10, and 
T20 extracts performed quiet well though not as 
well as Koroneiki extract. Thus, Koroneiki 
extract was the best inhibitor of both nucleation 
and fibril elongation. 
 
Olive  Fruit Extracts Do Not Inhibit the 
Change in αSN Structure induced by Vesicles 
Interaction with anionic phospholipid 
vesicles induces a major increase in α-helical 
structure in αSN (35) (Fig. 3E). Compounds such 
as squalamine can displace αSN from lipid 
membranes and decrease the α-helical content of 
αSN (36). However, even at the high 
concentration of 0.15 mg/ml, none of the extracts 
prevented monomeric αSN from forming an α-
helical structure in the presence of anionic 
vesicles of DMPG (Fig. 3F). Consistent with this, 
the Koroneiki extract failed to show any effect at 
other concentrations (0.025-0.3 mg/ml, data not 
shown). 
 
Olive  Fruit Extracts Are Nontoxic, Show 
Antioxidant Activity, and Decrease the Level 
of ROS in OLN-93 Cells  
We evaluated the antioxidant activity of the 
olive extracts at 0.02-0.12 mg/mL using the 
DPPH• assay. All extracts showed similar dose-
response levels in this assay (Fig. S5A). Further, 
none of the extracts showed significant toxicity 
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on their own towards OLN-93 and SH-SY5Y 
cells according to the MTT assay (Fig. S5B and 
Fig. S5E).  
We used DCFH-DA to evaluate extract 
effects on ROS production in OLN-93 cells. All 
extracts except T24 decreased free radical 
formation (Fig. S5C). Further, all extracts 
neutralized the deleterious effect of 100 µM H2O2 
(Fig. S5D) to the same concentration-
independent extent. 
 
Olive Fruit Extracts Induce Formation of Less 
Toxic Aggregates and Reduce the Cytotoxicity 
of Oligomers to the SH-SY5Y Cells 
We evaluated the membrane 
permeabilization and cytotoxicity of aggregates 
formed during different stages of αSN fibrillation 
with and without extracts (Fig. 4A). Without 
extracts, the ability of aggregates to release 
calcein decreased as the aggregates aged over 24 
h (Fig. 4B); several of the extracts, particularly 
Koroneiki, accelerated this decline. This suggests 
that aggregates formed in the presence of the 
extracts interact less with the membranes.  
In the MTT cell viability assay with OLN-
93 and SH-SY5Y cells, aggregates formed in the 
presence of the extracts showed less cytotoxicity 
than the extract-free αSN control samples (Fig. 
4C and 4D). The aggregates were more toxic to 
OLN-93 cells (Fig. 4C) than to SH-SY5Y cells 
(Fig. 4D). While all extracts significantly 
enhanced viability of OLN-93 cells at the early 
stages (4, 8, and 12h), at 24 h this effect is just 
significant for T17, Rowghani, and Koroneiki 
extracts. However, for SH-SY5Y cells, this 
enhancement effect is retained for all extracts and 
all incubation times (Fig. 4D).  A difference in 
response by different cell lines is not without 
precedent; we have also recently reported that 
SH-SY5Y and PC-12 cells (another neuronal cell 
line) differ in their sensitivity to αSN aggregates 
(37).  
We needed to rule out that the reduced 
toxicity of aggregates formed in the presence of 
the extracts could be caused by a general effect of 
the extracts on the cells. Therefore, we treated 
SH-SY5Y cells with Koroneiki extract, incubated 
for 2 h, removed the solution and washed with 
PBS. Subsequently we added αSN aggregates 
both to extract-treated and untreated cells. We 
found no significant difference in aggregate 
toxicity on the two cell types (data not shown), 
ruling out a general extract effect. 
Mitochondrial disruption induced by the 
aggregates was evaluated by the release of lactate 
dehydrogenase (LDH) (Fig. 4E). The aggregates 
formed without the extracts increased LDH 
release by 60-72 % compared to control. 
However, LDH release was reduced significantly 
in cells treated with aggregates formed in the 
presence of the extracts. This is consistent with 
reduced cellular toxicity and confirmed that 
extracts reduce the toxicity of aggregates in the 
cell-based assays. 
In the next step, the membrane 
permeabilization assay (Fig. 5A) was carried out 
to see if Koroneiki extract can decrease the 
membrane-disrupting ability of αSN oligomers, 
which permeabilize the membrane (and by 
inference induce toxicity in cells). Fig. 5B shows 
that Koroneiki extract only leads to an 
insignificant reduction in oligomer-induced 
permeabilization of anionic phospholipids in a 
calcein release assay. The Koroneiki extract itself 
does not lead to any calcein release and loss of 
vesicle integrity (data not shown).  
We finally tested the Koroneiki extract for 
its effect on oligomer toxicity in a cellular context 
(Fig. 5C). Purified oligomers decreased viability 
by 28 % on their own but only by 15% in the 
presence of 0.15 mg/ml Koroneiki extract. Thus, 
Koroneiki extract not only led to formation of less 
toxic and less cell-permeabilizing oligomers (Fig. 
4 B-D), but also protected SH-SY5Y cells against 
preformed toxic oligomers (Fig. 5C). Koroneiki 
extract at 0.015 mg/ml did not significantly 
reduce the toxicity of oligomers (data not shown).  
 
The Chemical Composition of Different 
Extracts  
HPLC analysis of the most effective extracts 
revealed the same qualitative but different 
quantitative phenolic composition for major 
components (Fig. S6). For more detailed studies, 
the Koroneiki extract was fractionated by 
UHPLC (Fig. S7), after which the inhibitory 
effect of the fractions was studied and the best 
fractions in inhibiting αSN fibrillation and 
reducing toxicity of αSN oligomers were 
analyzed on LC-MS to identify the compounds 
involved.  
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Identification of the Most Effective Fractions  
In the first step, the effect of fractions of the 
Koroneiki extract on αSN fibrillation was studied 
at two different concentrations. These are 
designated L and H (Low and High). L and H 
fractions are obtained from 1 mg/ml and 3 mg/ml 
Koroneiki extract, respectively, which implies 
that the concentration of the factions in the 
fibrillation assays are much less than 1 mg/ml and 
3 mg/ml. The most effective fractions (5, 6 and 
17-26) are indicated in red in Fig. S8A and S8B, 
while the time profiles of fibrillation are shown in 
Fig. S9. CD and TEM images were used to 
confirm the ThT data and better understand their 
effect on αSN fibrillation. CD data (Fig. 6A and 
6B) show that the most effective fractions 
maintained the unfolded secondary structure of 
αSN . The effect of the fractions at 3 mg/mL on 
the morphology of endpoint αSN aggregates was 
analyzed by TEM (Fig. S10). In the presence of 
the fractions, either only oligomers (f5, 18, 21, 
23, and 25) or both short fibrils and oligomers (f6, 
17, 19, 20, 24, and 26) were detectable. In 
contrast, the control sample without the koroneiki 
extract fractions only showed long straight fibrils. 
To determine whether or not the fractions 
affect elongation of existing fibrils, we incubated 
monomeric αSN with 5% αSN seeds. Fractions 
19, 20, 21, 22, and 23 were the best inhibitors of 
secondary nucleation (Fig. 6C). The other 
fractions did not completely inhibit seeded 
fibrillation but instead decreased the rate of 
elongation, increasing the time it took for the ThT 
fluorescence to reach a plateau level. 
The effect of the top 12 fractions identified 
in the ThT assay on the level of small and large 
oligomers and their ability to disaggregate 
existing fibrils of αSN was also studied. Fractions 
6, 18, 21, 22, 23 led to the formation of more 
small oligomers (Fig. S11A). Disaggregation of 
αSN fibrils by Koroneiki fractions also led to the 
formation of soluble oligomers (Fig. S11B) and 
fractions 5, 20, 24, 25, 26 were the most effective. 
 
Identification of the Antioxidant Activity and 
Toxicity of Different Koroneiki Extract 
Fractions 
We evaluated the antioxidant activity of the 
Koroneiki fractions u sing the DPPH• assay. 
Fractions with the most inhibitory effect (f5, 6, 
17-26) showed more inhibition (%) and 
scavenging ability (Fig. S12A). When these 
fractions were incubated with OLN-93 and SH-
SY5Y cells, they showed no significant toxicity 
at 1 and 2 mg/mL (Fig. S12B and S12C); 
however, fractions 19, 21, 23, and 25 were 
slightly toxic to OLN-93 cells at the highest 
concentration tested (3 mg/mL). 
 
The Most Effective Fractions Induce the 
Formation of Less Toxic Aggregates 
The same toxicity assay as for whole 
extracts was used to evaluate the toxicity of 
formed aggregates during the fibrillation process 
either in the presence or absence of the Koroneiki 
fractions. The calcein release assay showed a 
reduction in the interaction of the aggregates 
formed up to 24 h in the presence of fractions 
with the membranes compared to the control 
samples (Fig. 6D). In the cell assay on both OLN-
93 and SH-SY5Y cells, the toxicity of control 
aggregates formed up to 8 h increased and then 
decreased slightly. Aggregates formed in the 
presence of the Koroneiki fractions also generally 
showed an increase in cytotoxicity at early stages, 
but the levels of toxicity were reduced compared 
to control, in particular for fraction 25 (Fig. 6E 
and F). Overall, the LDH assay in SH-SY5Y cells 
also confirmed these data (Fig. 6G).  
 
Separation and Identification of Phenolic 
Compounds in the Most Effective Fractions 
We used LC-MS analysis of the most 
effective Koroneiki fractions to separate and 
identify major components of these fractions. 
Identification of the compounds was done based 
on accurate mass measurements of the [M-H]¯ 
ion and their MSMS fragmentation patterns as 
documented in the literature. The total ion current 
(TIC) profiles of representative olive fractions are 
presented in Fig. S13. Data obtained from high 
resolution MS analysis of the fractions are 
summarized in Table S2. The major compounds 
in each fraction are listed in Table S3 and 
indicated on the TIC profiles of individual 
fractions (Fig. S13). It is clear that the single 
largest family of compounds consists of 
oleuropein and derivatives thereof. For additional 
insight, we tested individual compounds 
identified in the Koroneiki fractions, namely 
verbascoside, loganin, rutin, elenolic acid, 3- 
Hydroxytyrosol, and oleuropein. The compounds 
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effects on αSN fibrillation were tested through 
ThT-based kinetics, CD spectroscopy and TEM 
imaging (Fig. 7). ThT data (Fig. 7A) show that 
verbascoside, elenolic acid, 3-hydroxytyrosol and 
oleuropein completely inhibit fibrillation at 50 
(verbascoside) or 100 µM (all other compounds), 
comparable to the effect of EGCG (38). The CD 
data (Fig. 7B) also show that these compounds 
keep αSN in its monomeric unfolded state better 
than other compounds. Finally, TEM images of 
αSN after incubation in the presence of 
oleuropein confirm the absence of fibrils (Fig. 
7C). 
 
Correlating the Change in the Chemical 
Compositions of Extracts with their Inhibitory 
Effect  
We also analyzed extracts from developing 
fruits to correlate the change in the chemical 
composition of the extracts with their inhibitory 
effect. During the ripening process and fruit 
development, the phenolic content changes (31). 
Accordingly, we collected olive fruits at different 
ripening time and the effect of the extracts was 
tested on αSN fibrillation. The HPLC data and the 
effect of the extracts are shown at Fig. S14. Then 
the average values of the end ThT values of αSN 
aggregation in the presence of different amounts 
of olive extracts (the 9 top-ranked extracts as well 
as extracts of fruits collected at different ripening 
times) were combined with the HPLC data of the 
olive samples to analyze the effect of different 
compounds in the extracts. The “peakutils” 
Python package was used to identify peaks in the 
HPLC data. Finally, a correlation analysis was 
performed to determine which peaks have 
correlated amounts across all of the samples. This 
analysis confirmed that the compound eluting as 
oleuropein aglycone, which also shows the 
highest m-value as a measure of its anti-
fibrillation potency, is of interest since the level 
of that compound was not well correlated with 
other compounds and was therefore more likely 
to be responsible for the difference in inhibition 
across the extracts (Table 1). Comparison of 
HPLC chromatograms of extracts of fruits picked 
at different ripening time with their inhibitory 
effect (Fig. S14) revealed that the extracts with 
higher level of oleuropein aglycone had more 
inhibitory potency; in contrast, the levels of other 
compounds were lower compared to the less 
effective extracts. 
 
Discussion  
In PD, αSN aggregation initiates a cascade 
of molecular events leading to neuronal death. As 
a consequence, the identification of small 
molecules able to interfere in vivo with 
aggregation of αSN is a vital strategy against PD. 
Here we address three questions to identify olive 
oils with maximal anti-aggregative effects: 
1) What is the mechanism behind the inhibiting 
effect of beneficial polyphenols? 
2) Can these polyphenols lead to the formation of 
less toxic aggregates?  
3) How do the level of beneficial polyphenols 
change with time? 
 
The Best Extracts in inhibiting αSN 
fibrillation Inhibit Both Nucleation and 
Elongation of αSN 
A summary of the efficacy of the olive 
extracts and the Koroneiki extract fractions in 
different assays is shown in Tables 2 and 3, 
respectively. We scored each assay between 0 
and 1 and then determined the final ranking. We 
classified extracts of 7 out of 15 different olive 
varieties according to their efficacy in inhibiting 
distinct steps of αSN aggregation (nucleation and 
elongation). Although the ranking differed 
slightly in different assays, all assays emphasized 
the remarkable inhibitory effect of the Koroneiki 
extract as the best inhibitor of both nucleation and 
elongation. Koroneiki, 'the queen of olives', is a 
variety with particularly good oil quality 
characteristics, making it the main olive oil 
produced in Greece (39). Koroneiki and T20 
varieties were most effective in the 
disaggregation assay, whereas Rowghani, which 
had performed well in the other assays, 
performed poorly here. These extracts may 
interact with the hydrophobic residues of β-sheet 
and cause disaggregation of amyloid fibrils. The 
different rankings indicate that these extracts are 
likely to bind both nuclei and fibril surfaces and 
ends, but to different extents. 
 
The Best Extracts in inhibiting αSN 
fibrillation Favor Less Toxic Oligomeric 
Species  
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Inhibition of aggregation could bypass the 
formation of toxic prefibrillar aggregates and 
direct αSN towards less toxic aggregates. SEC 
analysis and SDS-PAGE were used to analyze the 
aggregates that form in the presence of the 
extracts. Interestingly, Koroneiki extract, which 
was the best inhibitor, also ranked top in the 
formation of small oligomers and only led to a 
low production of large oligomers, while the T23 
extract, which performed poorly in all other 
assays, strongly favored large oligomers. The 
SDS-PAGE results also indicate that the great 
majority of the αSN remains monomeric and the 
TEM images showed a reduction in longer fibrils 
at the fibrillation assay endpoint in the presence 
of the extracts. We therefore conclude that the 
most promising extracts inhibit SN 
amyloidogenesis by retaining αSN in the 
monomeric state, and incorporating minor 
amounts of SN monomers into highly stable 
oligomers that are non-cytotoxic and off-pathway 
to fibrillogenesis (16), thereby inhibiting the 
subsequent growth phase (Fig. 8).  
This change in the aggregation process also 
reduces cytotoxicity. Co-incubation of 
monomeric SN with Koroneiki extracts lead to 
the formation of aggregates that – particularly 
after longer incubation - permeabilized 
membranes significantly less than the control 
aggregates and were less toxic to OLN-93 and 
particularly to SH-SY5Y cells. Some compounds 
are known to inhibit the membrane interactions of 
preformed SN oligomers (16, 40). This is not 
the case for Koroneiki extract, which did not 
reduce the interaction of SN monomers or 
preformed SN oligomers with membranes, so 
the reduction in cytotoxicity of preformed SN 
oligomers must derive from another as yet 
unknown mechanism, rather than by reducing 
membrane interactions.  
SN is susceptible to oxidative stress which 
in turn favors its aggregation (41), and oligomeric 
species formed in the aggregation process can 
induce oxidative stress (42). Therefore, extracts 
and compounds that inhibited both SN 
aggregation and reactive oxygen species (ROS) 
production would be promising. The extracts 
themselves showed no toxicity to OLN-93 and 
SHSY5Y cells. All extracts showed significant 
antioxidant activity and neutralized the 
deleterious effect of H2O2 on cells with different 
potency. This protective effect other than the 
scavenging of free radicals could be due to the 
effect at the molecular level of the cells such as 
activation of signaling cascades and regulation of 
calcium ion homeostasis (43).  
 
Oleuropein aglycone, Hydroxyoleuropein 
aglycone, and Oleuropein Are Mainly 
Responsible for the Difference in Inhibition 
across the Extracts 
An understanding of the molecular 
mechanism of olive extract-induced inhibition is 
complicated by the polyphenolic complexity as 
evidenced by LC-MS. In addition to polyphenols, 
such as flavonoids found in many fruits, 
oleuropein and other glucosides structurally 
related to this compounds are present exclusively 
in olive plants. Using the same assays as used for 
ranking the extracts, the inhibitory effect of 
fractions of the Koroneiki extract was tested on 
SN fibrillation. Phenolic compounds present in 
the inhibitory extracts were identified as 
hydroxytyrosol, hydroxytyrosol glucoside, 
oleuside, rutine, verbascoside, 6'-(E)-p-
coumaroyl-secologanoside, and compounds 
structurally related to oleuropein, such as 
dihydrooleuropein, hydroxyoleuropein, 
oleuropein glucoside, hydroxyoleuropein 
aglycone, and oleuropein aglycone (Table S3) . 
Some of these compounds are commercially 
available and the others can be chemically 
synthesized or isolated from olive sources. The 
effects of some of the compounds on fibrillation 
of proteins and their antioxidant potency have 
been studied before (22–24). The fractions 
containing the most effective compounds were 
ranked in different assays (Table S5). As shown 
for the extracts, the isolated fractions also have 
different effects in the assays used in this study 
(Table 3). Some extracts have more fibrillation 
inhibitory potency (f5, 19, 20, 21, 22, 24), some 
are better in inhibition elongation (f5, 6, 19, 20, 
21, 22), some produce more small oligomers (f18, 
21, 22), some are more effective in 
disaggregation of preformed fibrils (f5, 20, 24, 
25, 26), and some of them were excellent in 
decreasing the formation of toxic aggregates (f5, 
17, 20, 21, 26). Interestingly, all the fractions with 
the highest inhibitory effect (f5, 6, 17-26) showed 
higher ROS scavenging ability.  
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HPLC analysis showed that the content of 
the polyphenols of olive fruit depends on olive 
cultivar and ripening stage of the fruit, which 
leads to a different effect on the fibrillation 
process and the formed SN species, antioxidant 
activity and ROS scavenging and toxicity. To 
correlate the change in the polyphenol content of 
the extracts with their inhibitory effect, we 
compared the level of the compounds based on 
the height of the peaks in each extract with the 
end ThT values in a correlation analysis (Table 
1). This analysis shows that oleuropein aglycone, 
hydroxyoleuropein aglycone, and oleuropein are 
the main compounds responsible for the 
difference in inhibition across the extracts. 
Koroneiki as the most inhibitory cultivar contains 
the maximum level of oleuropein aglycone 
compared to the other varieties. This correlation 
in the extracts of same varieties picked at 
different ripening stages is also clear. Most of the 
compounds in olive oil result from spontaneous 
oleuropein hydrolysis and processing (44). The 
hydrolysis of oleuropein by an endogenous β- 
glycosidase during ripening leads to formation of 
oleuropein aglycone, which is the key compound 
responsible for the protective effect of olive oils. 
There are other studies on the inhibitory effect of 
oleuropein aglycone on fibrillation of 
aggregation-prone proteins. Palazzi et al (27) 
recently demonstrated that oleuropein aglycone 
hampers the growth of on-pathway SN 
oligomers and favors growth of stable and 
harmless aggregates. Further, oleuropein 
aglycone reduces the toxicity of SN aggregates 
by interfering with their binding to cell 
membrane components. These data are in 
accordance with our own findings that olive 
compounds rescue cells from the toxicity of SN 
aggregates. Oleuropein aglycone also interferes 
with the in vitro aggregation of human amylin 
and Aβ42 and redirects the aggregation pathway 
towards non-toxic aggregates, and interferes with 
Aβ42 proteotoxicity in vivo in transgenic 
C.elegans strains expressing Aβ42 by reducing 
plaque load and motor defect (20, 44, 45).  
In summary, we conducted a systematic 
study of the effect of fruit extracts of different 
olive varieties on SN fibrillation, 
oligomerization and toxicity, and antioxidant 
activity to select phenol-rich olive varieties with 
maximal effective phenolic content to counteract 
the development of PD hallmarks. We conclude 
that the polyphenols in olive fruits play a 
significant role in protection against PD. More 
specifically, we conclude that polyphenols can 
reduce SN aggregate toxicity through their 
antioxidant activity and direct aggregation 
towards non-toxic species. Our results contribute 
to the wider discussions concerning the 
mechanism of action of polyphenols in 
aggregation and toxicity prevention. Evaluation 
of the protection against PD by olive extracts and 
polyphenols in cell and animal models and 
development of nanocarriers to increase the 
bioavailability of olive polyphenols would be an 
interesting further step to drug development for 
PD. This will be useful not only for PD but also 
for assessing the potential of polyphenols in olive 
oils for future applications.  
 
Experimental procedures  
 
Materials  
Penicillin–streptomycin, fetal bovine serum 
(FBS), and Dulbecco’s Modified Eagle Medium 
(DMEM) were purchased from Gibco BRL 
(Gaithersberg, MD, USA). 1,2-dioleoyl-sn-3-
phosphatidyl-glycerol (DOPG) were from Avanti 
Polar Lipids (Alabaster, AL). Lactate 
dehydrogenase (LDH) measurement kit was from 
Pishtazteb Co. (Iran). All other chemicals were 
from Sigma Aldrich (St. Louis, MO). 
 
Olive Fruit Samples 
Three distinct categories of olive varieties 
were studied (Table S1). The first group, the 
Tarom varieties (T), consists of nine Iranian olive 
varieties including T10, T15, T16, T17, T18, 
T20, T22, T23 and T24 (46). The second group 
consists of three Mediterranean varieties 
including Koroneiki, Arbequina and Picual. The 
third group consists of three major varieties in 
Iran including Zard, Mari, and Rowghani. All the 
studied olive trees were nearly 18 years old, 
reproduced by taking cuttings from the mother 
plant, irrigated and fertilized by a drip system at 
Tarom olive research station. All trees samples 
were in the same orchard under the same 
environmental conditions. Three replicated plants 
were studied. The fruits were picked at 180 days 
after full bloom (DAFB) corresponding to 
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different developmental stages for the different 
olive tree varieties. Samples were stored at -20°C 
on the same day of picking (47).  
 
Extraction of Phenolic Compounds From 
Olive Fruits 
The fresh mesocarp (3 g) was frozen in 
liquid nitrogen and ground to fine powder in a 
porcelain mortar. It was then mixed with 
methanol (12 mL) and vortexed for 1 min at 
20°C. The resulting mixture was centrifuged 
(3500 rpm at 4°C) for 20 min. The supernatant 
was separated, lyophilized and stored at -20 °C.  
 
Protein Production and Purification 
 Recombinant human αSN was expressed in 
Escherichia coli BL21(DE3) strain with a 
plasmid vector pET11-D using auto-induction 
(48). Briefly, the pelleted cells were resuspended 
in 100 mL osmotic shock buffer (30 mM Tris-
HCl, 40 % sucrose, 2 mM EDTA, pH 7.2), and 
incubated for 10 min followed by centrifugation 
(9000 g, 20 °C, 30 min). The resulting pellet was 
resuspended in 90 mL ice-cold deionized water 
and 40 µL of saturated MgCl2 was added, 
followed by incubation on ice for 3 min. The 
supernatant after centrifugation (9000 g, 4 °C, 
and 20 min) was precipitated by titration with 1 
M HCl to pH 3.5 and then incubated for 5 min. 
The supernatant was collected by centrifugation 
(9000 g, 4 °C, and 20 min) and immediately 
titrated to pH 7.5 with 1 M NaOH, filtered (0.2 
µm) and loaded on a Q-Sepharose column 
(HiTrap Q H P) pre-equilibrated with 20 mM 
Tris-HCl pH 7.5. Then, αSN was eluted with a 
NaCl gradient from 0.1-0.5 M. The fractions were 
analyzed using SDS-PAGE and the collected 
purified αSN was dialyzed exhaustively against 
deionized water, lyophilized and stored at -20 °C. 
 
Protein and Extract Handling 
Prior to use, freshly dissolved αSN in PBS 
buffer, pH 7.4, was filtered (0.2 µm). Protein 
concentration was measured by absorbance 
measurements at 280 nm with a NanoDrop™ 
1000 spectrophotometer (Thermo Scientific) 
using a theoretical extinction coefficient of 0.412 
(mg/mL)-1. All olive fruit extracts used in the 
screening assays were freshly dissolved in PBS 
buffer and filtered (0.2 µm) prior to use. 
 
Plate Reader Fibril Formation Assays 
αSN fibril formation was carried out as 
described (33). Briefly, 150 µL PBS solution 
containing 70 µM (1 mg/ml) αSN, 40 µM ThT 
and varying amounts of methanolic olive extracts 
was added to each well of a 96-well-plate (Nunc, 
Thermo Fischer Scientific, Roskilde, Denmark) 
with a 3 mm diameter glass bead, sealed with 
Crystal clear sealing tape (Hampton Research, 
Aliso Viejo, CA, USA). The fibrillation was 
followed at a Genios Pro fluorescence plate 
reader (Tecan, Mänerdorf, Switzerland) at 37 °C 
with 300 rpm orbital shaking between the 
readings for 12 min. Samples were excited at 448 
nm and emission was measured at 485 nm.  
The dose-response aggregation inhibition 
curves fitted a simple binding isotherm: 
𝑇ℎ𝑇௘௡ௗ ௟௘௩௘௟ ൌ ሺ𝑇ℎ𝑇଴ െ 𝑇ℎ𝑇௠௜௡ሻሺ1 െሾை௟௜௩௘ ௘௫௧௥௔௖௧ሿ
௄ವାሾை௟௜௩௘ ௘௫௧௥௔௖௧ሿሻ ൅ 𝑇ℎ𝑇௠௜௡   (1)  where ThTend level is the ThT fluorescence 
level at the end of the fibrillation process at a 
given olive concentration, ThT0 is the ThT 
fluorescence end level in the absence of 
compounds, ThTmin represents the ThT level at 
maximum inhibition, [Olive extract] is the 
concentration of the olive extract and KD is the 
mole ratio needed for half inhibition.  
The Finke-Watzky (F-W) (49) equation was 
fitted to the normalized ThT fibrillation data: 
𝐹ሺ𝑡ሻ ൌ  ଵଵା௘షరഔሺ೟ష೟భ/మሻ  (2) 
𝑡ே ൌ 𝑡ଵ/ଶ െ ଵଶఔ    (3)   where t½ is the time required to produce half 
the total product, ν is the rate of growth at t½ and 
tN is the duration of the nucleation (lag) phase 
(31) . 
 
Seeding Experiments 
The fibril elongation assays were performed 
using a plate reader setup with the same settings 
as for the fibrillation assay in the presence of 0.05 
mg/mL seeds (corresponding to 3.5 µM 
monomer) and 0.15 mg/ml olive extracts in a 
solution of 70 µM monomeric SN in 96-well 
plates. The snap-frozen mature fibrils were 
thawed and fragmented by sonication for 2 min 
on ice (pulse 5 s. on and 5 s. off) with an 
amplitude of 20 % on a QSonica Sonicators 
(Q500, Newtown, CT, USA) to obtain short 
fibrils, which were employed as seeds.  
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Fibril Disaggregation Assays  
The fibril stock solution was prepared using 
the same setting as for the fibrillation assay and 
the fibrils. Aggregated αSN (35 µM monomer 
equivalents) was incubated overnight either alone 
or with the olive extracts (0.15 mg/mL) at 37 °C. 
The solution was centrifuged (21000 g, 20 min) 
and the supernatant was injected onto a 24 mL 
Superose 6 10/300 gel filtration column (GE 
Healthcare Lifescience) at 0.5 mL/min to 
separate monomers and oligomeric species. 
 
Preparation of Oligomers 
αSN oligomers were prepared as previously 
described (16). Briefly, 12 mg/mL αSN was 
incubated in PBS buffer for 5 h at 37 °C and 900 
rpm on an Eppendorf thermoshaker, TS-100, 
BioSan, Latvia. The sample was then centrifuged 
(21000 g, 10 min) to remove insoluble material 
and the supernatant was loaded on an a Superose 
6 Prep Grade column, GE healthcare Life 
Sciences, Sweden, in PBS at 2.5 mL/min. Small 
oligomers were collected and were concentrated 
with 15 mL Amicon ultracentrifugal filters 
(Merck). 
 
Preparation of Large Unilamellar Vesicles 
(LUVs) 
LUVs were prepared as described (50). 
Briefly, 1, 2-dioleoyl-sn-3-phosphatidylglycerol 
(DOPG) or 1,2-dimyristoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (sodium salt) (DMPG) 
was dissolved at 5 mg/ml in PBS. The solution 
was subjected to 10 freeze thaw cycles between 
liquid nitrogen and a 50 °C water bath. The lipid 
solution was extruded 21 times through a 100 nm 
filter. To prepare calein loaded vesicles, calcein 
at self-quenching concentrations (70 mM) was 
added to the phospholipids and after extrusion, 
the vesicle solution was run through a PD-10 
desalting column (GE Healthcare) to separate 
free calcein from calcein loaded vesicles. 
 
Analyzing Soluble SN Remaining in Solution  
To analyze soluble SN remaining in the 
solution, samples were taken from the plate after 
24 h incubation and pelleted by centrifugation for 
10 min at 21000 g. This speed can pellet large 
fibrillar aggregates, leaving in the supernatant 
monomers and oligomers which do not even 
pellet during ultracentrifugation unless bound to 
e.g. phospholipid vesicles (51). We are able to 
discriminate monomers and oligomers by SDS-
PAGE since the latter are SDS-resistant (10). The 
supernatant was mixed with SDS-PAGE sample 
loading buffer and heated for 2 min at 95 °C 
before loading on a 15% SDS-PAGE gel. The 
supernatant was also run on a Superose 6_10/300 
gel filtration column. 
 
Circular Dichroism (CD) Spectroscopy 
For far-UV CD, sonicated fibril solutions 
with protein concentration of 0.2 mg/mL (14 μM) 
were placed in a 1 mm cuvette and the spectra 
were measured from 250 to 195 nm at 25 °C with 
a Jasco J-810 spectrophotometer (Jasco 
Spectroscopic Co. Ltd., Japan). To measure the 
induced changes in the secondary structure of 
αSN by DMPG vesicles and the effect of olive 
samples on this interaction, 0.2 mg/mL (14 μM) 
of αSN was mixed with 0.2 mg/mL of DMPG 
vesicles in the presence and absence of 0.15 
mg/ml of olive samples in PBS buffer at 37 °C. 
CD spectra of PBS buffer and the olive solutions 
were recorded and subtracted from the protein 
spectra and the CD signal given as mean residue 
ellipticity (degrees cm2 dmol-1). 
 
Transmission Electron Microscopy (TEM) 
αSN sample in 5 µL PBS buffer was 
transferred to a carbon-coated, glow-discharged 
400-mesh grid for 30 s. The grids were washed 
using 2 drops of double distilled water, stained 
with 1% (w/v) phosphotungstic acid (pH 6.8), 
and blotted dry. The samples were viewed in a 
microscope (JEM-1010; JEOL, Tokyo, Japan) 
operating at 60 kV. Images were obtained using 
an Olympus KeenView G2 camera. 
 
Oligomerization Assays 
αSN monomer (1 mg/mL) was incubated on 
an Eppendorf TS-100 thermoshaker (BioSan, 
Latvia) with 0.15 mg/mL of olive extracts for 1 h 
at 37 °C and 900 rpm. The solution was 
centrifuged (21000 g, 20 min) and the supernatant 
was injected into a 24 mL Superose 6 10/300 gel 
filtration column at 0.5 mL/ min. Samples from 
both oligomerization and disaggregation assays 
were run on an SEC-MALS system (Wyatt 
Technology Europe) using separation on a 
Superose 6_10/300 gel filtration column and 
analyzed using 18-angle static laser light 
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scattering (Dawn Heleos II), refractive index 
(Optilab T-rEX differential refractometer) and 
absorbance at 280 nm (Agilent 1260 Analytical 
UV cell). Data was collected and analysed using 
the software ASTRA 6.1.7.17 (Wyatt 
Technology Europe). 
 
Calcein Release Assays 
The membrane permeabilization assay was 
carried out to compare the membrane-disrupting 
ability of different αSN aggregates that form in 
the presence and absence of the extracts. 
Oligomers permeabilize the membrane (and by 
inference induce toxicity in cells) much more 
efficiently than fibrils. Permeabilization of 
vesicles due to the interaction with oligomers 
results in calcein release and an increase in the 
fluorescence signal due to dilution. Calcein-
loaded DOPG vesicles at a final lipid 
concentration of 42 µM were loaded in triplicate 
in a 140 µL assay solution onto a 96-well plate 
(Nunc, Thermo Fisher Scientific, Roskilde, 
Denmark). The background fluorescence at 
excitation 485 nm and emission at 520 nm was 
measured on Genios Pro fluorescence plate 
reader (Tecan, Mänerdorf, Switzerland) before 
and after addition of vesicles. The olive extracts 
and/ or oligomers at a final concentration of 0.02-
0.2 mg/mL and 0.5 µM, respectively, were mixed 
with vesicles in a final volume of 150 µL. The 
plates were sealed with crystal clear sealing tape 
(Hampton Research, Aliso Viejo, CA, USA) and 
calcein release was measured for 1 h at 37 °C 
every 1.5 min with 2-s autoshake before each 
reading. Finally, 1 µL Triton X-100 (0.1% (w/v)) 
was added to lyse vesicles, leading to complete 
calcein release and maximal fluorescence signal. 
Background fluorescence was subtracted. 
 
HPLC Analysis of Phenolic Compounds in 
Different Olive Fruit Extracts 
The extracts were analyzed with an Ultimate 
3000 model HPLC, run on a RP-C18 Luna 
column, 4.6 mm id×250 mm and particle size 5 
µm (Phenomenex, UK). For each injection 
(50 μL), elution was performed at a flow rate of 1 
mL/min, using a solvent system of water/TFA 
(1%) (A) and acetic acid/TFA (1 %) (B). Elution 
was started with 5 % B, and continued with a 
gradient to 35 % B at 45 min, 90 % B at 55 to 57 
min and then reduced to 5 % B at 61 min. 
Chromatograms were recorded at 230 nm.  
 
Fractionation of Koroneiki Extracts by HPLC 
Dried extracts were reconstituted using 1.75 
mL of water. Fractionation was carried out using 
an HPLC system (Dionex UltiMate 3000, 
Thermo Fisher Scientific) equipped with an 
Ascentis C-18 column (5 μm, 5 × 250 mm, 
Supelco, UK). Chromatographic separation was 
performed using a constant flow rate of 1 mL/min 
of the mobile phases water/0.1% formic acid (A) 
and acetonitrile/0.1% formic acid (B). The binary 
gradient was: 0–10 min, 5% B; 10–50 min, 22% 
B; 50–60 min, 37% B; and finally 60–70 min, 
50% B. Fractions were collected every 2.5 min 
between 5 and 70 min (T1-T26). Twelve 
injections (100 μL each) were performed and 
fractions from repeated runs were combined. 
Thirty μL of each fraction was diluted with 270 
μL of 80/20 (v/v) water/methanol and 
subsequently analysed by UHPLC-MS. The 
remainder of each fraction was dried using a 
Speedvac concentrator (Genevac, Suffolk, UK).  
 
Identification of Phenolic Compounds in 
Koroneiki Extract Fractions by uHPLC-MS 
To identify the compounds, Ultra High 
Performance Liquid Chromatography-Mass 
Spectrometry (uHPLC-MS) were recorded with 
an Ultimate 3000 RS uHPLC system, equipped 
with a DAD-3000 photodiode array detector, 
coupled to an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Scientific, Germany). An 
injection volume of 10 µL was used and the 
elution was performed on a reversed-phase C18 
Hypersil gold column (1.9 µm, 30 x 2.1 mm i.d., 
Thermo, Hemel Hempstead, UK), at 35 °C, using 
a solvent system consisting of water/0.1% formic 
acid (A) and acetonitrile/0.1% formic acid (B) 
under the following conditions: 0–5 min, 0% B; 
5–27 min, 31.6% B; 27–34 min, 45% B; 34–
37.5 min, 75% B at a flow rate of 0.3 mL/min. 
Mass spectra were collected using an LTQ-
Orbitrap Elite with a heated ESI source (Thermo 
Scientific, Germany). Mass spectra were 
acquired in negative mode with a resolution of 
120,000 over m/z 50-1500. The source voltage, 
sheath gas, auxiliary gas, sweep gas and capillary 
temperature were set to 2.5 kV, 35 (arbitrary 
units), 10 (arbitrary units), 0.0 (arbitrary units) 
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and 350 °C respectively. Default values were 
used for other acquisition parameters. Automatic 
MS-MS was performed on the 4 most abundant 
ions using an isolation width of m/z 2. Ions were 
fragmented using high-energy C-trap dissociation 
(HCD) with a normalized collision energy of 65 
and an activation time of 0.1 ms. Data analysis 
was carried out using Xcalibur v. 2.2 (Thermo 
Scientific, Germany). Compounds were 
identified on the basis of their retention time, 
accurate mass and MSMS fragmentation patterns. 
Where possible, known compounds were 
compared to authentic standards if available. 
Where this was not possible, a comparison to the 
reported MSMS fragmentation data was made for 
known compounds. Compounds where structural 
data could not be verified were labelled as 
unknown. A full table of the LC-MS data was 
prepared, including details of identification 
method for each component and reference data 
for known compounds (Table S2). 
 
Antioxidant Activity  
The antioxidant activity of the olive extracts 
was determined by monitoring the disappearance 
of DPPH• in the presence of olive extracts at 517 
nm. Olive extracts (20 µl) at various 
concentrations was mixed with 200 µl of DPPH• 
solution (0.135 mM). The resulting medium was 
incubated at room temperature in darkness for 30 
min. The antioxidant activity was determined 
using the following formula: 
Antioxidant activity = (Abs517control - 
Abs517sample)/Abs517control ×100   (4) 
  
ROS assay 
To assess whether olive extracts interfered 
with the level of ROS within the cells, 2´, 7´-
dichlorodihydrofluorescein diacetate (DCFH-
DA) was used. OLN 93 cells were seeded in 96-
well plates at a density of 6⤬104 cells/mL and 
incubated in a humidified atmosphere incubator 
at 37°C for 24 h. The medium was then removed 
and the cells washed with PBS and replaced by 
PBS containing 15 μM DCFH-DA. The plate was 
incubated for 45 min in the dark in a CO2 
incubator. DCFH-DA was removed and the wells 
were washed with PBS, treated with culture 
medium containing olive extracts in the absence 
or presence of 100 µM H2O2 and incubated at 
37°C (for 1 h) after which fluorescence of DCF 
was recorded in a microtiter plate reader 
(excitation / emission: 490/527 nm). 
 
Evaluation of Cell Viability  
The 3-[4, 5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay was 
implemented to measure cellular viability after 24 
h treatment by monomeric or aggregated forms of 
αSN. OLN-93 and SH-SY5Y cells were seeded 
in 96-well plates at a concentration of 30×103 and 
60×103 cells/mL, respectively, in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented 
with 10 % (v/v) fetal bovine serum (FBS), 100 
units/mL penicillin, and 100 µg/mL streptomycin 
and cultured for 24 h. The medium was then 
replaced with fresh medium containing different 
concentrations of olive extracts or with 12.5 % 
αSN samples (collected during the fibrillation 
process). After 24 h at 37 °C, the old medium was 
replaced with fresh medium containing 10 % 
MTT (5 mg/mL), and the plates were incubated 
for an additional 4 h at 37 °C. To avoid possible 
interference between antioxidant compounds and 
the MTT assay, the cells were washed to remove 
aggregates and compounds before adding MTT. 
The formazan crystals were dissolved in 100 µL 
DMSO by incubating for 1 h on a shaking table 
at room temperature. Finally, absorbance was 
determined by a plate reader at 570 nm using 650 
nm as a reference wavelength. Cell viability was 
calculated as follows:  
Cell viability (%) = (Abs570 (Treated cells)/ 
Abs570 (Control cells) ×100  (5) 
 
LDH Assay 
Release of cytoplasmic enzyme, lactate 
dehydrogenase (LDH), as the sign of loss of 
membrane integrity was measured. After the 
treatment of the cells with αSN samples, 100 µL 
of growth medium was added to 1 ml of the kit 
substrate and absorbance at 340 nm was 
determined for 4 min to follow the conversion of 
NADH to NAD+. The values were expressed as a 
percentage of the untreated cells as control. 
 
Analysis of HPLC Elution Profiles 
The average values of the end ThT values of 
αSN aggregation in the presence of different 
concentrations of olive extracts and HPLC data of 
the olive extracts were used to analyze the effect 
of different compounds in the olive fruit extracts. 
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The “peakutils” Python package 
(https://bitbucket.org/lucashnegri/peakutils) was 
used to identify peaks in the HPLC data and the 
“sklearn” Python package (http://scikit-
learn.org/stable/) to cluster them as follows: 
a. The threshold for identifying peaks (the 
minimum height) was set to 750 A.U. 
b. The minimum distance between peaks was set 
to 50 data points. 
c. All of the peaks identified in this way (across 
all of the datasets) were compiled into a single list 
of peaks, and a k-means clustering was used to 
cluster the peaks into 5 groups. 
d. The cluster centers were extracted and used to 
identify the peaks in further analyses. 
For each peak that was identified, a relative 
measure of the “amount of compound” in each 
sample was determined by multiplying the 
concentration of the extract (mg/mL) by the 
height of the peak. Where the data was available, 
the “amount of compound” was plotted against 
the ThT signal. Data points with ThT signals 
below 1000 (arbitrary unit) were excluded from 
further analysis under the assumption that these 
corresponded to maximal inhibition and therefore 
might obscure attempts to determine whether the 
concentration of the compound was related to the 
level of the ThT signal in the relevant range 
(between 7000 and 1000 units). For each 
compound, the coefficient of determination (R2), 
and Spearman’s rank correlation coefficient were 
computed, and an isotonic regression model was 
built from the data. The R2 value measures the 
goodness of fit assuming a linear model, while the 
Spearman’s rank correlation coefficient measures 
how monotonically related the two quantities are 
without making an assumption about the 
functional form of the relation. R-squared values 
are always positive and between 0 and 1. 
Spearman R values can be in the range of -1 to 1. 
The isotonic regression generates an optimal 
monotonic fit to the data. The slope of the optimal 
linear fit (the m-value) was taken a measure of 
potency, with larger (negative) slopes 
corresponding to more potent inhibition. Finally, 
a correlation analysis was performed to determine 
which peaks had correlated amounts across all of 
the samples.  
 
 
Statistical Analysis 
Data were obtained in triplicate and 
averaged. The results are shown as mean ± 
standard deviation (SD). Statistical differences 
between group means were analyzed by analysis 
of variance (ANOVA). A value of p < 0.05 was 
considered statistically significant. 
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Table 1. For each olive extract constituent, coefficient of determination (R2), the slope of the optimal 
linear fit (m-value) and Spearman’s rank correlation coefficient for each compound. 
Peak elution time Compound R-Squareda m-valueb Spearman Rc 
35.5 Oleuropein 0.29 -11.76 -0.73 
28.5 Verbascoside 0.39 -24.69 -0.71 
50.3 Oleuropein aglycon 0.48 -88.31 -0.76 
40.0 Hydroxyoleuropein aglycone 0.24 -24.13 -0.72 
a Coefficient of determination: measures the goodness of fit assuming a linear model. 
b The slope of the optimal linear fit (the m-value): measures the potency with larger (negative) slopes 
corresponding to more potent inhibition. 
c Spearman’s rank correlation coefficient: measures how monotonically related the two quantities are 
without making an assumption about the functional form of the relation. 
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Table 2. Ranking of the top 7 olive variety extracts in different assays. 
  
Assay T10 T17 T20 T23 T24 Rowghani Koroneiki Ref. 
Inhibiting aggregation a  ++++ ++ +++ ++ +++ ++++ ++++ Fig. 1 
Inhibiting secondary 
nucleation b 
++++ +++ ++++ ++ +++ +++ ++++ Fig. 3 
Formation of small 
oligomers c 
+++ +++ ++ ++ ++ ++ ++++ Fig. 3 
Formation of large 
oligomers d 
++ ++ + ++++ ++ +++ + Fig. 3 
Inducing formation of less 
toxic aggregates to SH-
SY5Y cells during 
fibrillation e 
++++ ++++ +++ +++ +++ ++++ ++++ Fig. 4 
a at 0.1 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % 
inhibition, and ++++ 75-100 % inhibition. 
b at 0.15 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % 
inhibition, and ++++ 75-100 % inhibition. 
c at 0.15 mg/ml of the olive extracts, Min [small oligomer] = A, Max [small oligomer] =B, x ൌ ୅ି୆ସ .  + denotes A<[small oligomer]<A+x, ++  denotes A+x <[small oligomer]<A+2x, +++ denotes A+2x<[small 
oligomer]<A+3x, and ൅൅൅൅ denotes A+3x<[small oligomer]<B. 
d The same formula for ranking as in note c, this time using the large oligomers. 
e Average of toxicity of aggregates formed over different time ranges compared to control.  
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Table 3. Ranking of the fractions in different assays. 
 
Assay 5 6 17 18 19 20 21 22 23 24 25 26 Ref. 
Inhibiting  
aggregation 
a  
++++ ++ ++ +++ ++++  ++++  ++++  ++++  +++ ++++ +++ ++ Fig. 6 
Inhibiting  
secondary 
nucleation b 
++++ ++++ ++ ++ ++++ ++++ ++++ ++++ ++  ++  ++  ++  Fig. 6 
Formation 
of small 
oligomers c 
++ +++ ++ ++++ +++ +++ ++++ ++++ +++ ++  ++  ++  Fig. 
S11 
Inducing 
formation 
of less toxic 
aggregates 
to SH-
SY5Y cells 
during 
fibrillation d 
++++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ Fig. 6 
 
a at 0.1 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % 
inhibition, and ++++ 75-100 % inhibition. 
b at 0.15 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % 
inhibition, and ++++ 75-100 % inhibition. 
c at 0.15 mg/ml of the olive extracts, Min [small oligomer] = A, Max [small oligomer] =B, x ൌ ୅ି୆ସ .  + denotes A<[small oligomer]<A+x, ++ denotes A+x <[small oligomer]<A+2x, +++ denotes A+2x<[small 
oligomer]<A+3x, and ൅൅൅൅ denotes A+3x<[small oligomer]<B. 
d Average of toxicity of aggregates formed over different time ranges compared to control.  
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 Fig. 1. The effect of the extracts on αSN fibrillation. (A) The effect of 0-0.3 mg/ml of the olive extracts on the kinetics 
of αSN fibrillation at 5 different concentrations monitored by ThT fluorescence. Joined lines show Finke-Watzky 
model fitted to the experimental data. (B) The effect of the selected extracts (7 out of 15 extracts) at different 
concentrations (0.025,0.05,0.1,0.15, and 0.3 mg/ml) on the maximum ThT fluorescence intensity. (C) ThT end-point 
levels are converted to % inhibition and fitted to to Eq.1 to calculate the IC50 of the extracts. (D-F) Kinetic parameters 
for αSN fibrillation as a function of various concentration of the extracts relative to the values in the absence of the 
extracts ((D) relative growth rate (ν/ ν,control), (E) relative half time (t½/t½, control), and (F) relative lag time (tN/tN, control)). 
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 Fig. 2. Far-UV CD spectra of αSN incubated alone (control) and in the presence of (A) 0.3 mg/ml, (B) 0.15 mg/ml, 
and (C) 0.1 mg/ml of the 7 selected extracts after 24 h. (D) Normalized β structure (%) of αSN incubated in the 
presence of the 7 selected extracts. (E) SDS-PAGE analysis of the supernatants of the incubated samples of αSN in 
the absence and presence of 0.15 and 0.3 mg/ml of the best extracts in inhibiting αSN fibrillation. Monomeric αSN 
has a molecular weight of 14.5 kDa. Arrows highlight dimers (≈35 kDa) and oligomers (> 250 kDa). (F) The SEC-
profile of the supernatants of the samples of αSN incubated for 24 h with or without 0.15 mg/ml of Koroneiki extract. 
(G) Electron microscopy of αSN after 24 h incubation in the absence (control) and presence of 0.3 mg/ml of the 7 
selected olive fruit extracts. Scale bar, 200 nm. The size and distribution of the fibrils in each sample are summarized 
in the table below Fig. 2G. The length of fibrils were obtained in three TEM images for each sample and averaged. 
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 Fig. 3. The SEC-profile of the supernatants of the (A) samples of αSN incubated for 1 h and (B) preformed αSN fibrils 
preincubated overnight with or without 0.15 mg/ml of Koroneiki extract. The effect of the extracts (0.15 mg/ml) on 
the seeding of αSN aggregation under (C) shaking and (D) non- shaking condition. (E) Schematic representation of 
the α-helix structure induced in αSN by DMPG vesicles. (F) The effect of the extracts (0.15 mg/ml) on the interaction 
of monomer (14 µM ) and DMPG vesicles (0.2 mg/ml). 
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Fig. 4. (A) Schematic representation of the effect of olive variety extracts on the membrane permebilization and 
cytotoxicity of αSN aggregates. (B) Calcein release from DOPG vesicles after 20 min incubation with αSN aggregates 
formed alone and in the presence of the best extracts (0.3 mg/ml) over different times (0-24 h). Viability of (C) OLN-
93 and (D) SH-SY5Y cells after 2-24 h incubation with αSN aggregates formed alone and in the presence of the best 
extracts (0.3 mg/ml) over different times (0-24 h). (E) Cytotoxicity of αSN aggregates to SH-SY5Y cells was assayed 
by LDH-release. LDH signals were normalized to untreated cells. For all assays, values represent means ± SD and the 
differences between the groups and αSN control are significant (P < 0.05) unless markd "ns". 
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 Fig. 5. (A) Schematic representation of the effect of Koroneiki extract fractions on the membrane permebilization and 
cytotoxicity of αSN aggregates. (B) Calcein release from DOPG vesicles induced by oligomers (0.1 µM) either alone 
or in the presence of Koroneiki (0.2 mg/ml). The Koroneiki extract is used at the highest concentration at which 
quenching of fluorescence does not happen. (C) Viability of SH-SY5Y cells incubated with αSN oligomers with or 
without co-incubation with Koroneiki (0.15 mg/ml). 
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Fig. 6. (A) Far-UV CD spectra of αSN incubated alone (control) and in the presence of 3 mg/ml of Koroneiki extract 
fractions. (B) Normalized β structure (%) of αSN incubated in the presence of Koroneiki extract fractions. (C) The 
effect of the Koroneiki extract fractions (1.5 mg/ml) on the seeding of αSN aggregation under shaking conditions. 
(D) Calcein release from DOPG vesicles after 20 min incubation with αSN aggregates formed alone and in the 
presence of Koroneiki extract fractions (3 mg/ml) over different times (0-24 h). Viability of (E) OLN-93 and (F) 
SH-SY5Y cells after 24 h incubation with αSN aggregates formed alone and in the presence of Koroneiki extract 
fractions (3 mg/ml) over different times (0-24 h). (G) Cytotoxicity of αSN aggregates to SH-SY5Y cells was 
assayed by LDH-release. LDH signals were normalized to untreated cells. For all assays, values represent means ± 
SD and the differences between the groups and αSN control are significant (P < 0.05) unless it has "ns" mark. 
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Fig. 7. The effect of Koroneiki compounds on fibrillation of 1 mg/ml αSN. (A) The kinetics of αSN 
fibrillation in the presence of 0-200 µM of Koroneiki compounds, monitored by ThT fluorescence. (B) Far-
UV CD spectra of αSN incubated alone (Ctrl) and in the presence of 200 µM of Koroneiki compounds after 
24 h. (C) Electron microscopy of αSN after 24 h incubation in the presence of 200 µM oleuropein. Scale 
bar: 200 nm. 
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Fig. 8. Schematic representation of screening of different olive varieties. (1) The first screening of fruit extract of 15 
different olive varieties on the kinetic analysis of αSN fibrillation. (2) The most effective variety, Koroneiki, combined 
strong inhibition of αSN fibril nucleation and elongation with strong ability to disaggregate preformed fibrils and 
prevent formation of toxic αSN oligomers. (3) Koroneiki fruit extract was fractionated and by using the same assay 
as the ones used in step 2, the most effective fractions were identified. LS-MS analysis was further used to identify 
the major compounds in the effective fractions. Correlation analysis confirmed oleuropein aglycone, 
hydroxyoleuropein aglycone, and oleuropein as key compounds responsible for the difference in inhibition across the 
extracts. 
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Supplementary Figures 
 
  
Fig. S1. The effect of different olive fruit extracts on αSN fibrillation. First screening: Selection of the best extracts by 
the effect of (A) 0.025 mg/ml extract and (B) 0.3 mg/ml extract on the end-point ThT fluorescence level at 1 mg/ml αSN. 
 
 
  
Fig. S2. SDS-PAGE analysis of the supernatants of samples of 1 mg/ml αSN incubated for 24 h in the presence of 0-0.3 
mg/ml of of Koroneiki extract. Arrows highlight dimers (≈35 kDa) and oligomers (> 250 kDa). 
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 Fig. S3. Oligomerization assay. (A) SEC profile of the supernatants from solutions of 1 mg/ml αSN incubated for 1 h at 
37oC in the presence of different extracts. (B) Area under the peaks of small and large oligomers formed in the absence 
(Ctrl) and presence of 0.15 mg/ml of the best extracts. 
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Fig. S4. Disaggregation assay. SEC profile of the supernatants of preformed αSN fibrils incubated at 0.5 mg/ml overnight 
at 37oC in the absence (Ctrl) and presence of 0.15 mg/ml of the best extracts. 
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Fig. S5. Antioxidant activity and toxicity of the olive extracts. (A) Antioxidant activity of different olive fruit extracts at 
different concentrations (0.02, 0.04, 0.08, 0.12 mg/ml) measured by DPPH assay. (B) Viability of OLN-93 cells after 24 
h incubation with the best olive extracts at different concentrations (0.025, 0.2, 0.5 mg/ml). (C) Oxidative stress in OLN-
93 cells treated with olive extracts at different concentrations determined by DCFH-DA assay. (D) Free radical scavaging 
ability of the olive extracts measured in OLN-93 cells treated with 100 µM H2O2. (E) Viability of SH-SY5Y cells after 
24 h incubation with 0-0.5 mg/ml of the best olive extracts. 
 
 
 
 
 
DP
PH
 ra
dic
al s
cav
eng
ing
 ac
tiv
ity
 (%
)
Ce
ll v
iab
ilit
y (
%)
Fre
e r
adi
cal
 fo
rm
atio
n (
a.u
)
Ctrl 0.025 0.2 0.50
50
100
150
200
250
300
OL.E Concentration (mg/ml)
% 
of 
fre
e r
adi
cal
 fo
rm
atio
n
T10
T17
T20
T23
Rowghani
Koroneiki
T24
(D)
Ctrl 0.025 0.2 0.50
25
50
75
100
125
150
OL.E Concentration (mg/ml)
T10
T17
T20
T23
Rowghani
Koroneiki
T24
(E)
5 
 
  
Fig. S6. HPLC chromatograms of the 7 most efficient anti-aggregative olive extracts, recorded at 230 nm. 
 
 
 Fig. S7. Chromatogram of Koroneiki extract using HPLC. Fractions T1-26 are indicated. The different were identified 
by HPLC-MS. 
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Fig. S8. The effect of (A) 1 mg/ml  and (B) 3 mg/ml of the Koroneiki extract fractions on fibrillation of 1 mg/ml αSN. 
Maximum ThT fluorescence intensity normalized to control (absence of extract). 
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Fig. S9. The effect of Koroneiki extract fractions (3 mg/ml) on the kinetics of fibrillation of 1 mg/ml αSN monitored by 
ThT fluorescence. 
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Fig. S10. TEM images of 1 mg/ml αSN incubated alone (control) and in the presence of 3 mg/ml of Koroneiki extract 
fractions. 
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(B) 
   
   
   
  Fig. S11. SEC profiles of the supernatants of (A) samples of 1 mg/ml αSN incubated for 1 h at 37oC in an oligomerization 
assay and (B) 0.5 mg/ml preformed αSN fibrils preincubated overnight at 37oC with and without 3 mg/ml of Koroneiki 
extract fractions in a disaggregation assay.  
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Fig. S12. (A) Antioxidant activity of Koroneiki extract fractions (3 mg/ml) measured by DPPH assay. Viability of (B) 
OLN-93 and (C) SH-SY5Y cells after 24 h incubation with 1-3 mg/ml Koroneiki extract fractions. 
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 Fig. S13. Total ion chromatograms of Koroneiki fractions  
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 Fig. S13 (cont’d). Total ion chromatograms of Koroneiki fractions.  
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Fig. S14. Change in the level of compounds in the extracts of fruits picked at different maturation time (3, 4, 5, and 6 
months after flowering) and their inhibitory effect on αSN fibrillation. HPLC chromatogram of the extracts (A, C, and 
E) and their effect on the maximum ThT fluorescence intensity (B, D, and F) 
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Table S1. Olive cultivars used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
Nr Olive Cultivar Abbreviation Origin Nr Olive Cultivar Abbreviation Origin 
1 Koroneiki - Greece 9 Chenaran T16 Iran 
2 Arbequina - Spain 10 Khoshe T17 Iran 
3 Picual - Spain 11 Parseh T18 Iran 
4 Mari - Iran 12 Majnon T20 Iran 
5 Rowghani - Iran 13 Tak T22 Iran 
6 Zard - Iran 14 Zarin T23 Iran 
7 Yaghout T10 Iran 15 Arghavan T24 Iran 
8 Gorgan T15 Iran     
16 
 
Table S2. LC-MS data of fractions f5, 6, and 17-26 of Koroneiki extract obtained from HPLC separation 
 
Peak Retention 
time 
(min) 
m/z Predicted ion 
formula 
Delta 
(ppm) 
MS-MS λmax Identity or Compound 
class 
How 
identified 
Previously 
observed 
in Olea 
species? 
(reference) 
1 7.63 153.0556 [C8 H9 O3]-  0.94 123 (C7H7O2) 281 Hydroxytyrosol authentic 
standard 
Yes (1) 
2 8.67 151.0401 [C8H7 O3]-  1.49 - 280 4-Hydroxyphenylacetate  Accurate 
mass.  
Yes (1) 
3 11.46 315.1086 [C14 H19 O8 ]- 1.29 153 (C8H9O3) 278 Hydroxytyrosol glucoside MSMS and 
literature 
dataa 
Yes (1) 
4 12.33 245.1034 [C11H17O6]- 1.39 - - Unknown - - 
5 12.41 389.1090 [C16H21O11]- 1.11 227 (C10H11O6), 183 
(C9H11O4), 165 
(C9H9O3), 121 
(C8H9O), 89 (C3H5O3) 
 Oleoside RT, MS, 
MSMS and 
literature 
datab 
Yes (2) 
6 13.25 407.1560 [C17H27O11]- 1.21 389 (C17H25O10), 377 
(C16H25O10), 357 
(C16H21O9), 313 
(C15H21O7), 183 
(C10H15O3), 151 
(C9H11O2), 113 
(C5H5O3), 101 
(C4H5O3), 89 
(C3H5O3) 
 Glucosyl 
acyclodihydroelenolic acid 
isomer I  
Putative 
from 
MSMS.  
Yes (3) 
7 13.55 407.1560 [C17H27O11]- 1.24 389 (C17H25O10), 377 
(C16H25O10), 357 
(C16H21O9), 313 
(C15H21O7), 183 
(C10H15O3), 151 
(C9H11O2), 113 
(C5H5O3), 101 
(C4H5O3), 89 
(C3H5O3) 
 Glucosyl 
acyclodihydroelenolic 
acid.isomer II 
Putative 
from 
MSMS. 
Identical to 
Peak 6 
Yes (3) 
8 17.10 435.1506 [C18 H27 O12 ]- 0.877 357 (C16H21O9), 313 
(C15H21O7), 183 
(C10H15O3), 169 
(C9H13O3),  151 
(C9H11O2), 113 
(C5H5O3), 101 
219 Formate adduct of 
Loganin(C17H25O10) 
RT, MS, 
MSMS and 
literature 
datab 
Yes (2) 
17 
 
(C4H5O3), 89 
(C3H5O3) 
9 18.88 305.1038 [C16H17O6]- 1.82 153 (C8H9O3), 151 
(C8H7O3), 123 
(C7H7O2) 
217 Conjugate of hydroxytyrosol 
and hydroxyphenyl acetate 
(ie 4-(hydroxyphenyl)ethyl 
2-(4-hydroxyphenyl)acetate) 
OR conjugate of Vanillin 
and hydroxy tyrosol 
Putative 
based on 
MS/MSMS 
fragmentati
on 
- 
10 20.70 609.1514 [C27H29O16]-  1.17 300 (C15H8O7) 253, 354 Rutin Authentic 
standard 
Yes (2) 
11 21.08 653.2030 [C30H37O16]-  1.30 621 (C29H33O15), 459 
(C20H27O12 ), 179 
(C9H7O4), 161 
(C9H5O3), 151 
(C8H7O3) 
 Methoxyverbascoside RT, MS, 
MSMS and 
literature 
datab 
Yes (2) 
12 21.27 447.0934 [C21H19 O11 ]- 1.18 285 (C15H9O6) 346 Luteolin-7-glucoside Authentic 
standard 
Yes (2) 
13 21.35 453.2337 [C20H37 O11 ]- 0.63 321 (C15H29O7 ), 233 
(C9H13O7), 191 
(C7H11O6), 161 
(C6H9O5), 113 
(C5H5O3), 101 
(C4H5O3) 
218 Unknown - - 
14 21.46 241.0719 [C11H13 O6 ]- 0.169 139 (C6H3O4) 219.,328 Unknown -  
15 21.49 623.2022 [C22H39O20]- -0.71 461 (C16H29O15), 179 
(C9H7O4), 161 
(C9H5O3) 
330 Verbascoside RT, MS, 
MSMS and 
literature 
dataa 
Yes (1) 
16 21.50 505.2626 [C24H41O11]-  251 (C9H15O8 ), 191 
(C7H11O6), 149 
(C5H9O5), 131 
(C5H7O4), 101 
(C4H5O3), 89 
(C3H5O3) 
 Unknown diglycoside - - 
17 21.86 505.2625 [C24H41O11]-  373 (C19H33O7 ), 233 
(C9H13O7), 161 
(C6H9O5), 89 
(C3H5O3) 
 Unknown diglycoside - - 
18 21.89 465.2323 n.d.  333 (C16H29O7), 233 
(C9H13O7), 161 
(C6H9O5), 113 
(C5H5O3), 101 
218 Unknown  - 
18 
 
(C4H5O3), 89 
(C3H5O3) 
19 22.08 465.2332 n.d.  333 (C16H29O7), 233 
(C9H13O7), 161 
(C6H9O5), 113 
(C5H5O3), 101 
(C4H5O3), 89 
(C3H5O3) 
218 Unknown, isomer of 18 - - 
20 22.32 543.2047 
 
 
 
 
 
623.2041 
[C25H35O13]- 
 
 
 
 
 
[C22H39O20]- 
-2.55 
 
 
 
 
 
1.21 
377 (C16H25O10), 357 
(C16H21O9), 313 
(C15H21O7), 197 
(C10H13O4), 101 
(C4H5O3) 
 
461 (C16H29O15), 179 
(C9H7O4), 161 
(C9H5O3) 
 Dihydrooleuropein 
 
 
 
 
 
Verbascoside isomer 
RT, MS, 
MSMS. 
And refd 
Yes (4) 
 
 
 
 
 
Yes (2) 
21 22.73 701.2235 [C31H41O18]- -5.92 377 (C19H21O8), 307 
(C15H15O7), 275 
(C15H15O5), 221 
(C8H13O7), 179 
(C6H11O6), 149 
(C8H5O3), 101 
(C4H5O3) 
219 Oleuropein glycoside isomer RT, MS, 
MSMS. 
And ref b 
Yes (2) 
22 22.99 701.2213 [C31H41O18]- -7.44 377 (C19H21O8), 307 
(C15H15O7), 275 
(C15H15O5), 221 
(C8H13O7), 179 
(C6H11O6), 149 
(C8H5O3), 101 
(C4H5O3) 
219 Oleuropein glycoside isomer RT, MS, 
MSMS. 
And ref b 
Yes (2) 
23 23.01 447.0924 [C21H19O11]- -0.91 285 (C15H9O6) 328 Luteolin glycoside isomer By MSMS Yes (2) 
24 23.22 467.2479 [C21H39O11]- -0.81 335 (C16H31O7), 233 
(C9H13O7), 161 
(C6H9O5), 101 
(C4H5O3), 89 
(C3H5O3) 
219 Terpene diglycoside 
(Putative) 
- - 
25 23.32 551.1416 
 
 
701.2344 
[C21H27O14]- 
 
 
[C21H39O11]- 
1.94 
 
 
5.70 
161 (C9H5O3) 
 
 
539, 371 (C16H19O10), 
307 (C15H15O7), 275 
(C15H15O5), 223 
219 
 
 
220, 328 
cinnamoyl hydroxyloganin 
(PUTATIVE) 
 
Oleuropein-glucoside or 
Aleuricine A/B 
Putative;  
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(C11H11O5), 179 
(C6H11O6), 149 
(C8H5O3) 
26 23.43 381.1555 [C19H25O8]- 1.11 231 (C10H15O6 ), 201 
(C9H13O5), 183 
(C9H11O4), 151 
(C9H11O2,), 139 
(C8H11O2) 
 HT-ACDE. 
(Hydroxytyrosylacyldihydro
-elenolate) 
RT, MS, 
MSMS.  
Yes (5) 
27 23.54 573.2135 n.d.  345 (C15H21O9), 225 
(C12H17O4), 209 
(C10H9O5), 183 
(C9H11O4), 165 
(C9H9O3), 141 
(C7H9O3), 121 
(C8H9O) 
219 Unknown - - 
28 24.00 539.1771 [C25H31 O13 ]- 1.21 403 (C13H23O14),  223 
(C11H11O5), 179 
(C6H11O6),  119 
(C4H7O4), 113 
(C5H5O3), 101 
(C4H5O3), 95 (C6H7O) 
346 Oleuroside isomer MS, MSMS - 
29 24.10 549.2870 
 
 
 
377.1241 
n.d 
 
 
 
[C19H21O8]- 
2.32 
 
 
 
0.96 
417 (C21H37O8), 
233(C9H13O7), 161 
(C6H9O5). 
 
307 (C15H15O7), 275 
(C14H11O6), 149 
(C8H5O3), 139 
(C7H7O3), 127 
(C6H7O3), 111 
(C5H3O3), 111 
(C5H3O3), 101 
(C4H5O3), 95 (C6H7O) 
219 Unknown 
 
 
 
Oleuropein aglycone isomer 
 
 
 
 
RT, MS, 
MSMS. 
And ref b 
 
 
 
 
Yes (2) 
30 24.29 569.1924 
 
 
 
 
 
 
527.2092 
 
 
[C26H33 O14 ]- 
 
 
 
 
 
 
[C25H35O12]- 
-4.11 
 
 
 
 
 
 
4.72 
537 (C25H29O13) 403 
(C17H23O11), 371 
(C16H19O10 ), 305 
(C15H13O7), 223 
(C11H11O5), 151 
(C8H7O3) 
 
377 (C16H25O10 ), 313 
(C15H21O7), 
101(C4H5O3) 
 Methoxyoleuropein 
 
 
 
 
 
 
Coumaroyl bearing 
derivative 
RT, MS, 
MSMS. 
And ref b 
 
 
 
 
MSMS 
 
 
Yes (2) 
 
 
 
 
 
 
 
 
 
20 
 
 
377.1241 
 
307 (C15H15O7), 275 
(C14H11O6), 197 
(C10H13O4), 165 
(C9H9O3), 149 
(C8H5O3), 139 
(C7H7O3), 121 
(C8H9O), 111 
(C5H3O3), 111 
(C5H3O3), 101 
(C4H5O3), 95 (C6H7O) 
 
 
Oleuropein aglycone isomer 
 
RT, MS, 
MSMS. 
And ref b 
 
 
Yes (2) 
31 24.61 539.1745 [C25H31 O13 ]- -1.44 403 (C13H23O14),  371 
(C16H19O10), 307 
(C8H19O12), 275 
(C15H15O5), 223 
(C11H11O5), 179 
(C6H11O6),  149 
(C8H5O3) 119 
(C4H7O4), 101 
(C4H5O3), 95 (C6H7O) 
222, 282 Oleuropein RT, MS, 
MSMS. 
And ref b 
 
Yes (2) 
32 24.90 535.1430 [C25H27 O13 ]- -1.61 389 (C16H21O11),  345 
(C15H21O9), 307 
(C15H15O7), 265 
(C13H13O6), 235 
(C12H11O5), 205 
(C11H9O4),  163 
(C9H7O3) 145 
(C9H5O2), 121 
(C8H9O) 
219, 312 6'-(E)-p-coumaroyl-
secologanoside 
MS, MSMS Yes (4) 
33 25.16 539.1730 
 
[C25H31 O13 ]- 
 
1.91 
 
403 (C13H23O14),  327 
(C18H15O6), 307 
(C15H15O7), 275 
(C15H15O5), 223 
(C11H11O5), 197 
(C10H13O4),  165 
(C9H0O3), 149 
(C8H5O3) 139 
(C7H7O3), 119 
(C4H7O4), 101 
(C4H5O3), 95 (C6H7O) 
 
219 Oleuropein Isomer 
 
RT, MS, 
MSMS. 
And ref b 
 
Yes (2) 
34 25.35 565.1511 
 
[C26H29O14]- 
[ 
-4.04 
 
345 (C15H21O9), 295 
(C14H15O7), 235 
220, 327 Unknown 
 
- - 
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(C12H11O5), 193 
(C10H9O4), 175 
(C10H7O3), 161 
(C9H5O3) 
 
35 25.62 539.1793 [C25H31 O13 ]- 3.35 403 (C13H23O14),  371 
(C16H19O10), 327 
(C18H15O6), 307 
(C15H15O7), 275 
(C15H15O5), 223 
(C11H11O5), 197 
(C10H13O4),  165 
(C9H0O3), 149 
(C8H5O3) 139 
(C7H7O3), 119 
(C4H7O4), 101 
(C4H5O3), 95 (C6H7O) 
 Oleuroside Isomer MS,MSMS  
36 25.77 543.2459 [C26H39O12 ]- 2.31 375 (C16H23O10),  357 
(C16H21O9), 227 
(C12H19O4), 213 
(C10H13O5), 199 
(C11H19O3),  185 
(C10H17O3), 169 
(C9H13O3), 151 
(C9H11O2) 125 
(C7H9O2), 113 
(C5H5O3) 
220 Dihydro oleuropein RT, MS, 
MS-MS  
Yes (2) 
37 25.99 535.1479 [C25H27 O13 ]- 3.33 389 (C16H21O11),  345 
(C15H21O9), 307 
(C15H15O7), 265 
(C13H13O6), 235 
(C12H11O5), 205 
(C11H9O4),  163 
(C9H7O3) 145 
(C9H5O2), 121 
(C8H9O) 
220, 300 Coumaroyl-secologanoside 
isomer 
MS. MS-
MS 
 
38 26.30 377.1243 [C19H21 O8 ]- 0.29 307 (C15H15O7),  275 
(C14H11O6), 171 
(C7H7O5), 149 
(C8H5O3), 139 
(C7H7O3), 127 
(C6H7O3),  113 
(C5H5O3) 111 
220, 286 Isomer of oleuropein 
aglycone 
MSMS  
22 
 
(C5H3O3), 101 
(C4H5O3), 95 (C6H7O) 
39 26.60 523.1780 [C25H31 O12 ]- 3.12 361 (C19H21O7), 291 
(C15H15O6), 259 
(C15H15O4), 101 
(C4H5O3) 
220, 276 Ligstroside (or isomer) MSMS Yes (6) 
40 27.00 555.2100 [C26H35 O13 ]- 2.74 511 (C25H35O11) 345 
(C15H21O9),  327 
(C15H19O8), 225 
(C12H17O4), 197 
(C11H17O3), 183 
(C10H15O3), 165 
(C9H9O3), 155 
(C5H5O3),  139 
(C6H3O4), 121 
(C8H9O) 
220 Hydroxyoleuroside RT, MS, 
MSMS and 
refb 
Yes (2) 
41 27.15 493.1330 [C23H25 O12 ]- -1.04 327 (C15H19O8),  209 
(C10H9O5), 183 
(C9H11O4), 165 
(C9H9O3), 135 
(C8H7O2), 121 
(C7H5O2) 
220 Unknown   
42 27.46 555.2040 [C26H35 O13 ]- -3.20 345 (C15H21O9),  327 
(C15H19O8), 225 
(C12H17O4), 197 
(C11H17O3), 183 
(C10H15O3), 165 
(C9H9O3), 155 
(C5H5O3),  139 
(C6H3O4), 121 
(C8H9O) 
220 Hydroxyoleuroside isomer MS, MSMS  
43 27.70 377.1243 [C19H21O8]- 0.21 307 (C15H15O7), 275 
(C14H11O6), 191 
(C10H7O4), 171 
(C7H7O5),   149 
(C8H5O3), 139 
(C7H7O3), 127 
(C6H7O3), 111 
(C5H3O3), 101 
(C4H5O3), 95 (C6H7O) 
220 Isomer of oleuropein 
aglycone 
RT, MS, 
MSMS and 
refb 
Yes (2) 
44 28.10 461.2013 [C21H33O11]- -0.43 167 (C10H15O2 )  Unknown - - 
23 
 
45 28.14 393.1191 [C19H21 O9 ]- 1.05 317 (C17H17O6),  181 
(C9H9O4), 137 
(C8H9O2) 
220 Hydroxyoleuropein 
aglycone 
Putative 
from 
MSMS data 
- 
46 28.29 557.2192 [C26H37 O13 ]- -3.68 345 (C15H21O9), 227 
(C12H19O4), 199 
(C11H19O3), 185 
(C10H17O3), 165 
(C9H9O3),   139 
(C6H3O4), 121 
(C8H9O) 
220,  6'-O-[(2E)-2,6-dimethyl-8-
hydroxy-2-
octenoyl]secologanoside 
MSMS data Yes (4) 
47 29.95 545.2563 n.d. - - - Unknown - - 
48 30.08 377.1242 [C19H21O8]- 1.10 307 (C15H15O7), 275 
(C14H11O6), 191 
(C10H7O4), 171 
(C7H7O5),   149 
(C8H5O3), 139 
(C7H7O3), 127 
(C6H7O3), 111 
(C5H3O3), 101 
(C4H5O3), 95 (C6H7O) 
 Oleuropein aglycone RT, MS, 
MSMS and 
refb 
Yes (2) 
49 31.19 377.1243 [C19H21O8]- 0.24 307 (C15H15O7), 275 
(C14H11O6), 191 
(C10H7O4), 171 
(C7H7O5),   149 
(C8H5O3), 139 
(C7H7O3), 127 
(C6H7O3), 111 
(C5H3O3), 101 
(C4H5O3), 95 (C6H7O) 
 Isomer of oleuropein 
aglycone 
MSMS data  
50 32.21 943.3442 [C43H59O23]- 0.05 513 (C35H29O4), 345 
(C15H21O9), 227 
(C12H19O4), 209 
(C10H9O5), 185 
(C10H17O3), 165 
(C9H9O3),   149 
(C8H5O3), 139 
(C6H3O4), 121 
(C8H9O), 101 
(C4H5O3) 
222 Unknown - - 
 
24 
 
Table. S3. Major compounds identified in fractions from the Koroneiki extract  
 
Nr Fraction Major compounds 
1 5 Hydroxytyrosol, Hydroxytyrosol glucoside, and Oleoside 
2 6 Acyclodihydroelenolic acid glucoside isomer, Loganin 
3 17 Rutin 
4 18 Verbascoside 
5 19 Dihydro oleuropein 
6 20 Oleuropein glucoside 
7 21 Oleuropein 
8 22 Oleuropein and Coumaroyl-secloganoside 
9 23 Dimethyl- Hydroxyoctenoyl-secologanoside 
10 24 Hydroxyoleuropein aglycone, Oleuropein aglycone 
11 25 Oleuropein aglycone 
12 26 Oleuropein aglycone 
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